CLINICAL TRIALS PROFILE FOR RALTEGRAVIR POTASSIUM
✉ Email this page to a colleague
All Clinical Trials for RALTEGRAVIR POTASSIUM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00293254 ↗ | A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-02-01 | This study will investigate the safety and efficacy of raltegravir as a therapy for Human Immunodeficiency Virus (HIV)-infected patients failing current therapy with 3-class antiviral resistance. |
| NCT00293267 ↗ | A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-02-01 | This study will investigate the safety and efficacy of raltegravir as a therapy for HIV-infected patients failing current therapy with 3-class antiviral resistance. |
| NCT00460382 ↗ | Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses | Completed | Janssen-Cilag Tibotec | Phase 2 | 2007-05-01 | The purpose of this study is to look at the safety and efficacy of a combination of 3 new antiretroviral drugs: darunavir, etravirine and MK-0518 (raltegravir) in patients who have multi-resistant viruses and limited treatment options. An optimized background regimen that may include nucleoside reverse transcriptase inhibitors (NRTIs) and enfuvirtide can be added, if possible, to this combination. Patients will undergo treatment for 48 weeks and virological efficacy will be evaluated at week 24. |
| NCT00460382 ↗ | Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses | Completed | Merck Sharp & Dohme Corp. | Phase 2 | 2007-05-01 | The purpose of this study is to look at the safety and efficacy of a combination of 3 new antiretroviral drugs: darunavir, etravirine and MK-0518 (raltegravir) in patients who have multi-resistant viruses and limited treatment options. An optimized background regimen that may include nucleoside reverse transcriptase inhibitors (NRTIs) and enfuvirtide can be added, if possible, to this combination. Patients will undergo treatment for 48 weeks and virological efficacy will be evaluated at week 24. |
| NCT00460382 ↗ | Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses | Completed | French National Agency for Research on AIDS and Viral Hepatitis | Phase 2 | 2007-05-01 | The purpose of this study is to look at the safety and efficacy of a combination of 3 new antiretroviral drugs: darunavir, etravirine and MK-0518 (raltegravir) in patients who have multi-resistant viruses and limited treatment options. An optimized background regimen that may include nucleoside reverse transcriptase inhibitors (NRTIs) and enfuvirtide can be added, if possible, to this combination. Patients will undergo treatment for 48 weeks and virological efficacy will be evaluated at week 24. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RALTEGRAVIR POTASSIUM
Condition Name
Clinical Trial Locations for RALTEGRAVIR POTASSIUM
Clinical Trial Progress for RALTEGRAVIR POTASSIUM
Clinical Trial Phase
Clinical Trial Sponsors for RALTEGRAVIR POTASSIUM
Sponsor Name
| Sponsor Name for RALTEGRAVIR POTASSIUM | |
| Sponsor | Trials |
| Merck Sharp & Dohme Corp. | 4 |
| ANRS, Emerging Infectious Diseases | 1 |
| French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) | 1 |
| [disabled in preview] | 2 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
